Phibro Animal Health Q2 EPS Beats by 26.1% with $373.9M Revenue Beat
Phibro Animal Health posted Q2 2025 adjusted EPS of $0.87, beating consensus by 26.1%, with revenues of $373.9 million exceeding estimates by 4.7%. The company’s 21.5% projected long-term earnings growth rate outpaces the industry’s 12.9%, following four straight quarters of at least 20.1% earnings surprises.
1. Q2 2025 Financial Results
Phibro Animal Health delivered Q2 2025 adjusted earnings per share of $0.87, topping consensus by 26.1%, while revenues of $373.9 million surpassed estimates by 4.7%. These results reflect strong operational execution across its core animal health and nutrition businesses.
2. Long-Term Growth Outlook
The company projects a long-term earnings growth rate of 21.5%, well above the industry average of 12.9%, driven by expanding global demand for its portfolio of animal health solutions and ongoing product innovation.
3. Consistent Earnings Surprises
Phibro has outperformed analyst expectations in each of the past four quarters, delivering an average earnings surprise of 20.1%, underscoring its track record of reliable fiscal performance.